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MINI-REVIEWAntimicrobial peptides of the vaginal innate immunity and their role in the
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Kashan and 5) Drug Design and Bioinformatics Unit, Department of Biotechnology Research Centre, Pasteur Institute of Iran, Tehran, IranAbstractSome antimicrobial peptides (AMPs) are produced in the vaginal innate immune system and play an important role in protecting this organ
against pathogenic agents. Moreover, sexually transmitted diseases have become a major problem in human societies and are rapidly
spreading. The emergence of antibiotic-resistant microbes (superbugs) can pose a major threat to human societies and cause rapid spread
of these diseases. Finding new antimicrobial compounds to fight superbugs is therefore essential. It has been shown that AMPs have good
potential to become new antibiotics. The most important AMPs in the vaginal innate immune system are defensins, secretory leucocyte
protease inhibitors, calprotectin, lysozyme, lactoferrin and elafin, which play an important role in host defence against sexually
transmitted infections, modulation of immune responses and anticancer activities. Some AMPs, such as LL-37, magainin 2 and nisin, show
both spermicidal and antimicrobial effects in the vagina. In this summary, we will discuss vaginal AMPs and continue to address some of
the challenges of using peptides to control pathogens that are effective in sexually transmitted diseases.
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(S. Sardari)IntroductionDefensins, secretory leucocyte protease inhibitors (SLPIs),
calprotectin, lysozyme, lactoferrin and elafin are groups of
antimicrobial peptides (AMPs) with effective roles in the innate
immunity of the vagina [1]. Some of the most importantThis is an open access artifunctions of these peptides in the vagina are shown in Fig. 1.
Sexually transmitted diseases (STDs) are defined as a group of
diseases that are transmitted from person to person through
sexual contact. It means that the infection has several methods
of spreading, such as vaginal intercourse, or anal and oral sex
[2]. Chlamydia trachomatis infection, chancroid (caused by
Treponema pallidum), gonorrhoea (Neisseria gonorrhoeae),
crabs (pubic lice), genital herpes (herpes simplex virus-2 (HSV-
2)), hepatitis B (hepatitis B virus), human immunodeficiency
virus (HIV)/AIDS, human papillomavirus (HPV), scabies,
trichomoniasis (Trichomonas vaginalis), molluscum con-
tagiosum virus and candidal vaginitis (Candida albicans) are
examples of the most important STDs [2,3].
The rapid growth and spread of these diseases is a major
threat to human health so research into the diagnosis and
treatment of these diseases should be taken seriously. Despite
all advances in the field of antibiotics, microbial resistance is a
significant issue that can eliminate the effects of most antimi-
crobial drugs a few years after their introduction as therapeuticNew Microbe and New Infect 2020; 34: 100627
© 2019 The Author(s). Published by Elsevier Ltd
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FIG. 1. Some important functions of antimicrobial peptides in the vagina.
2 New Microbes and New Infections, Volume 34 Number C, March 2020 NMNIcompounds. Recently, AMPs have been considered by many
scientists as suitable therapeutic compounds [4,5]. AMPs are
antimicrobial compounds produced by the innate immune
system of all organisms [6]. Much research has shown that
antimicrobial peptides and proteins can exert their antimicro-
bial effects on the pathogens that are effective in STDs [7–10].
Many of these peptides, including natural peptides derived from
the vaginal innate immune system and synthetic AMPs, have
been tested as antimicrobial compounds against the bacteria
and viruses that cause STDs. The results of all these tests
indicate that AMPs are suitable candidates for the fight against
STDs. For example, anti-HIV activity is one of the important
functions for both α- and β-defensins. α-Defensins have direct
inhibitory effects on viral replication [1,11] whereas β-defensins
inhibit viral entry into cells by reducing expression of its related
co-receptors [1]. Regulation of sex hormones is another
characteristic of some AMPs. Levels of α- and β-defensins in
cervico-vaginal lavage liquid vary during the menstrual cycle,FIG. 2. This figure represents the main mechanisms of action of antiviral pe
© 2019 The Author(s). Published by Elsevier Ltd, NMNI, 34, 100627
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licewith differences up to 50-fold [1,12]. Such differences in con-
centration indicate that levels of estrogen can affect the oper-
ational vaginal innate immunity status [1,13]. SLPIs have
inhibitory actions on HIV-1 [14], and women with lower genital
tract infections by T. vaginalis, C. trachomatis, N. gonorrhoeae
and Candida express lower SLPI levels [13]. Calprotectin con-
centrations have a direct relationship with inflammatory cyto-
kines in cervical mucus, proving that it has a key role in local
inflammation. Calprotectin also has anti-candida properties
[1,15]. Elafin, like defensins and SLPIs, has anti-HIV activity, and
there is evidence that the presence of elafin may lead to HIV
infection resistance [16].
AMPs that act against effective viruses in STDs
One of the AMP classes comprises anti-viral peptides, which
can inhibit the replication of viruses or prevent their patho-
genesis by various mechanisms (Fig. 2). For a long time HIV-1
infection as an STD was an insoluble global health problem.ptides.
nses/by-nc-nd/4.0/).
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this infection are needed [17]. A total of 109 anti-HIV pep-
tides have been registered in the AMP database or APD3
(http://aps.unmc.edu/AP/database/antiH.php/2019) up to
now. With advances in peptide stability, production, formu-
lation and delivery methods, it is possible that some of these
complexes may ultimately become the source of novel anti-
HIV agents and medications [17]. Some of the most impor-
tant of these peptides include defensins, LL-37 [18], grami-
cidin D, caerin1 [19], maximin 3, magainin 2, dermaseptin-S1,
dermaseptin-S4, siamycin I, siamycin II and RP 71955 (http://
aps.unmc.edu/AP/database/antiH.php/2019). Infection with
HSV-2 elevates the risk ratio of catching HIV from 2 to 4
[20,21]. Keratinocytes infected by HSV-2 release several
AMPs, including LL-37, which is the most notable peptide. LL-
37 increases the expression of the HIV-1 receptors CD4 and
CCR5 on T cells, which leads to elevation of the susceptibility
and possibility of catching HIV-1. Hence, cleaning LL-37 from
HSV-2-infected cells decreases the cells’ HIV-1 susceptibility
[18,20]. Innate immunity has a key role against HSV [22]. In
an in vitro study a complex of native cytokines and AMPs
(CCAP or Super lymph) had an inhibitory effect on virus
reproduction. Protegrines, as a CCAP element, have an active
role against the virus. The mechanism of this mentioned
CCAP is to produce both immune modulating and antiviral
effects [22]. In another study, a microbicide compound
combining the lipid-ether 1-0-octyl-sn-glycerol (OG; 3 mM)
and peptide D2A21 (9 μM) decreased the titers of herpes
simplex virus type 1 (HSV-1) and HSV-2 by at least 1000-fold,
more than the sum of the decreased titers under the in-
duction of OG and D2A21 alone [23]. There are other
compounds, like penaeidin-3, that have inhibited over 85% of
the HSV replication at 100 μM [24]. HPV is the cause of
common warts such as laryngeal papilloma and genital
condylomata and it can lead to cervical cancer [25]. Lacto-
ferrin acts as an antiviral compound against HPV-16 and other
types are under the influence of lactoferricin [25]. Successful
E6-binding peptides against HPV-16 have been identified [26].
Another study reported that β-defensin-1 peptide is a natural
shield against HPV in the mucosa of the genital tract [27].
Human α-defensins 1–3 (also called human neutrophil pep-
tides 1–3) and human α-defensin 5 have antiviral activities
against both cutaneous and mucosal papillomavirus types
[28]. The changes in AMP expression in vulvo-vaginal biopsies
from HPV-infected individuals compare with those from non-
infected people indicate that these peptides have key roles in
local immune responses. It is strange that human β-defenisin-
1 has a notable induction whereas RNase7 has not, so there is
different regulation of AMPs between bacterial and viralThis is an open access articinfections [29]. Given this, can these peptides be used in the
preparation of pre-sex lotions?
Antibacterial peptides that combat STDs
Data show that there are several antibacterial compounds that
combat STDs. For instance, in gonorrhoea, decreasing LL-37
expression gives a survival advantage in the female genital tract
to pathogenic Neisseria [30]. Another study introduced a cell-
penetrating peptide with 12 residues that was able to kill 100%
of N. gonorrhoeae strains at a concentration of 100 mM [31].
Another study on a new AMP revealed its ability to combat all
strains of N. gonorrhoeae, especially some reference and clinical
N. gonorrhoeae strains, such as penicillin-resistant strains. Der-
maseptin is a new AMP obtained from frog skin [32].
Other diseases can be treated by AMPs. Studies have indi-
cated the antibacterial effects of cathelicidin peptides against C.
trachomatis, Chlamydia pneumoniae and Chlamydia psittaci
[33] but Chlamydial Protease-Like Activity Factor (CPAF), a
serine protease that releases from C. trachomatis, can stop the
LL-37 anti-chlamydial activity due to CPAF’s proteolytic activity
[34]. Some studies revealed defensin and cathelicidin-derived
peptide activities against Leptospira, Borrelia and Treponema
pallidum, and an in vitro rabbit model showed that synthetic
truncated LL-37-derived peptide WS22–N-amide prevented T.
pallidum infection [35–37].
Another example of an AMP compound is cell-penetrating
peptide, Pep-1, which prevents the growth of intracellular,
but not extracellular, forms of C. trachomatis [38]. This bac-
teria is a human obligate intracellular pathogen and causes STDs
in both men and women [39]. In 2013, researchers studied the
anti-chlamydial activity of cyto-insectotoxin 1a (CIT 1a), a
unique class of AMP that was collected from some of a central
Asian spider’s venom – Lachesanatarabaevi [40].
Anti-parasitic and antifungal peptides against sexually
transmitted infections
Trichomoniasis. We know that AMP expression rises during T.
vaginalis infection in the cervix [41]. Trichomonas vaginalis is a
pathogen that causes trichomoniasis. There are two serious
problems with trichomoniasis. On the one hand, if it becomes
chronic the it can lead to more serious effects in patients, and on
the other, there are drug-resistant strains of T. vaginalis that
require novel clinical therapeutic compounds like AMPs to be
designed [42]. Metronidazole resistance in T. vaginalis can be
compensated for by epinecidin-1, which is a synthetic marine
AMP with anti-T. vaginalis activity. Epinecidin-1 in in vitro con-
ditions, destroys the membrane of T. vaginalis, and at a concen-
tration of 12.5 mg/L kills it [42,43]. C-amidated tritrpticin is an
antimicrobial tryptophan-rich peptide derived from a porcine
cathelicidin. It can disrupt T. vaginalis survival and growth [44]© 2019 The Author(s). Published by Elsevier Ltd, NMNI, 34, 100627
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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base or APD3 (http://aps.unmc.edu/AP/database/antiH.php/
2019) such as aureins, maximins, magainin, brevinin, rana-
tuerin and cecropins and also many synthetic peptides such as
AurH1, which derives from Aurein1.2 and 1127 other anti-
fungal peptides can effectively treat Candida albicans infection
[45]. Candidal vaginitis is the second most common vaginal
infection in the USA, that usually detect simultaneously by
physician in gynecologic problems [46].
Spermicide and microbicide peptides. Although there is only three
AMPs – LL-37, magainin 2 and nisin – of which the contraceptive
effects have been proved in animal models, there are many AMPs,
including LL-37, maximin 1, maximin3, magainin 2, dermaseptin-
S1, dermaseptin-S4, subtilosin A, pediocin PA-1/AcH, nisin A,
lacticin 3147, sarcotoxinPd and gramicidin A, that may have
ambivalent spermicidal/microbicidal activity (Fig. 1) [47,48].
However, there are two serious problem: infertility and disrup-
tion of the normal flora. Some AMPs, like nisin A, have a dual
killing effect on both microbes and beneficial commensal lacto-
bacilli that exist in the vagina. Lactobacilli are responsible for the
acidic pH in the healthy human vagina, so nisin A is not a good
choice as an antimicrobial drug [48]. On the one hand we have
cervicovaginal epithelial cells that naturally release LL-37 and on
the other it has spermicideal effects. Therefore, high levels of
natural LL-37 can cause infertility. Now there is a new question:
‘What factors can elevate the natural LL-37 production or release
from cervico-vaginal epithelial cells?’
DiscussionNew clinical procedures have some problems, for example,
antimicrobial peptide synthesis is a costly and time-consuming
procedure. To overcome such a problem, in silico analysis is
suggested before clinical experiments, which can decrease
production costs and activity time, and even down-regulate the
toxicity [4]. However, nowadays natural AMPs have clinical and
commercial functions so that we have many AMPs for every
pathogen responsible for sexually transmitted disease whether
bacteria and viruses or fungi, yeasts and protozoa. Some of
them have direct antimicrobial effects and can defend the host
against pathogens, and some are chemotactic agents that direct
the attention of inflammatory cells to the infection location
[1,4,49]. In future we have to improve their antimicrobial ac-
tivity and stability, and also minimize the cytotoxicity and
immunogenicity, and decrease the proteolytic self-destruction
or the biological fluid inhibition [4,50].
In conclusion we find LL-37 as a microbicidal AMP against
Chlamydia trachomatis, N. gonorrhoeae, Trpeonema pallidum,
Candida albicans, Staphylococcus aureus, Pseudomonas© 2019 The Author(s). Published by Elsevier Ltd, NMNI, 34, 100627
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceaeruginosa, Prevotella intermedia, Porphyromonas gingivalis,
Klebsiella pneumoniae, Escherichia coli, Enterococcus faecalis
and HIV and HSV [48]. LL-37 has several notable properties
such as dual spermicidal/microbicidal activity. It destroys the
sperm surface membrane and stops sperm motility in humans
and mice. This takes about 5 min with a dosage of 10.8 μM and
then 3.7 μM [48]. The LL-37 microbicidal activity affects STDs,
vaginitis and urinary tract infection by controlling involved mi-
croorganisms [48]. LL-37 used as a pharmaceutical gel and
administered into the vagina induces microbicidal effects on
uropathogenic opportunistic microbes. The vaginal secretions,
which contain both naturally secreted LL-37 and the LL-37
released from the gel can move from the vagina to the uri-
nary tract, where it can also exert its microbicidal effects [48].ConclusionAs mentioned above, AMPs, especially LL-37, can inhibit STDs.
Any new medical compounds containing LL-37 have problems
in several stages of their production, but changes in AMPs can
be made, such as structural changes or changes in method of
consumption, then LL-37 could have more benefits and fewer
limitations. First, there are economic problems in the produc-
tion stage; because LL-37 is a long peptide, it is expensive to
synthesize. Hence it is essential to discover a mimetic of the
shortest possible truncated LL-37 peptide with no decrease in
spermicidal and microbicidal activities, and to prepare recom-
binant LL-37. Novel methods like in silico analysis can have key
roles in solving this problem. Second, there are problems in the
delivery stage. It is necessary to find a method to deliver LL-37
into the human vagina [48]. Also in the consumption stage,
modified AMPs can be designed as ointments or topical lotions
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